ImClone: Suitor due diligence finished
ImClone Systems Inc., the New York cancer drug developer said to be in talks to be acquired by Indianapolis-based Eli Lilly and Co., disclosed late yesterday that the suitor had “completed due diligence and made a proposal not subject to financing or further due diligence.” ImClone didn’t identify the suitor, but said it is a […]